Genflow Biosciences plc Stock

Equities

GENF

GB00BP2C3V08

Biotechnology & Medical Research

Market Closed - London S.E. 11:35:11 2024-07-12 am EDT 5-day change 1st Jan Change
2.25 GBX -4.26% Intraday chart for Genflow Biosciences plc -6.25% +57.89%
Sales 2022 - Sales 2023 - Capitalization 4.17M
Net income 2022 -1M Net income 2023 -1M EV / Sales 2022 -
Net cash position 2022 2.36M Net cash position 2023 684K EV / Sales 2023 -
P/E ratio 2022
-5.26 x
P/E ratio 2023
-2.56 x
Employees 5
Yield 2022 *
-
Yield 2023
-
Free-Float 36.13%
More Fundamentals * Assessed data
Dynamic Chart
1 day-4.26%
1 week-6.25%
Current month-13.46%
1 month-31.82%
3 months+38.46%
6 months+36.36%
Current year+57.89%
More quotes
1 week
2.10
Extreme 2.1
2.50
1 month
2.10
Extreme 2.1
3.20
Current year
1.32
Extreme 1.3225
3.41
1 year
1.32
Extreme 1.3225
3.41
3 years
1.32
Extreme 1.3225
13.50
5 years
1.32
Extreme 1.3225
13.50
10 years
1.32
Extreme 1.3225
13.50
More quotes
Managers TitleAgeSince
Founder 66 19-12-31
Members of the board TitleAgeSince
Director/Board Member 64 22-06-28
Chairman 61 22-06-28
Founder 66 19-12-31
More insiders
Date Price Change Volume
24-07-12 2.25 -4.26% 501,733
24-07-11 2.35 +4.44% 567,567
24-07-10 2.25 -6.25% 543,488
24-07-09 2.4 0.00% 62,588
24-07-08 2.4 0.00% 29,459

Delayed Quote London S.E., July 12, 2024 at 11:35 am EDT

More quotes
Genflow Biosciences Plc is a United Kingdom-based biotechnology company. The Company is engaged in developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases, which is done through therapeutics targeting aging in humans by using adeno-associated virus (AAV) vectors to deliver copies of the Sirtuin-6 (SIRT6) gene variant that is found in centenarians into cells. The Company's product line includes GF-1002, GF-3001 and GF-4001. GF-4001. GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. GF-4001 is a non-human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs). GF-3001 is a formulation of an adeno-associated viral vector-based gene therapy. The Company has operations in the United Kingdom and Belgium.
More about the company